[1]黄坤林,刘玉金.紫杉醇- 顺铂方案经导管动脉灌注化疗治疗不可切除非小细胞肺癌的临床应用[J].介入放射学杂志,2020,29(06):612-616.
 HUANG Kunlin,LIU Yujin..The clinical application of transcatheter arterial infusion chemotherapy with TP regimen in treating unresectable non- small cell lung cancer[J].journal interventional radiology,2020,29(06):612-616.
点击复制

紫杉醇- 顺铂方案经导管动脉灌注化疗治疗不可切除非小细胞肺癌的临床应用()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年06
页码:
612-616
栏目:
临床研究
出版日期:
2020-06-25

文章信息/Info

Title:
The clinical application of transcatheter arterial infusion chemotherapy with TP regimen in treating unresectable non- small cell lung cancer
作者:
黄坤林 刘玉金
Author(s):
HUANG Kunlin LIU Yujin.
Department of Oncology Intervention, Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
关键词:
【关键词】 动脉灌注化疗 肺癌 非小细胞型 紫杉醇- 顺铂方案
文献标志码:
A
摘要:
【摘要】 目的 评价TP方案(紫杉醇- 顺铂)经导管动脉灌注化疗(TAI)治疗不可切除非小细胞肺癌(NSCLC)临床价值。 方法 随访64例行TP方案TAI治疗的不可切除NSCLC,分析预后相关因素及安全性。 结果 64例患者共接受172次TAI,平均每例(2.7±1.9)次。37例仅支气管动脉为肿瘤供血动脉,27例除支气管动脉外,还有肋间动脉、胸廓内动脉、胸外侧动脉、膈动脉参与供血。无严重TAI相关并发症。随访1~60个月,死亡63例。客观反应率为46.9%,疾病控制率为81.3%。全部患者肿瘤无进展的平均时间为6.7个月,中位无进展时间3个月。平均总生存时间(OS)9.8个月,中位OS 6个月。6个月、12个月、24个月累积生存率分别为54.7%、29.7%、9.4%。基于单因素分析,OS的独立影响因素是TAI治疗次数和更多的肿瘤供血动脉。 结论 TAI是治疗不可切除NSCLC安全、有效的方法,给不可切除NSCLC患者带来了明显的临床获益,可延长患者生存时间,提高生存质量,值得临床应用与推广。

相似文献/References:

[1]史诗洁,詹迎江,童林军,等.西艾克介入性治疗肝癌、肺癌的临床研究[J].介入放射学杂志,1998,(01):29.
[2]段天红.肺癌介入术中给药法的改进[J].介入放射学杂志,1998,(04):243.
[3]刘子江,袁建华,俞文强,等.肺癌支气管动脉灌注化疗引起食管支气管瘘[J].介入放射学杂志,1995,(01):15.
[4]杜建伟,方立德,倪锋,等.肺癌肺动脉介入治疗[J].介入放射学杂志,2000,(01):25.
[5]张玉锋.肠系膜上动脉灌注化疗治疗大网膜转移癌所致肠梗阻的疗效观察[J].介入放射学杂志,2015,(02):130.
 ZHANG Yu feng..Therapeutic efficacy of superior mesenteric arterial infusion chemotherapy for bowel obstruction caused by metastatic carcinoma of greater omentum[J].journal interventional radiology,2015,(06):130.
[6]汪继武,陈耀康,张 均,等.同轴凝血退针法在CT引导下经皮肺穿刺活检中的应用[J].介入放射学杂志,2020,29(05):468.
 WANG Jiwu,CHEN Yaokang,ZHANG Jun,et al.Application of coaxial thrombin needle withdrawal technique in CT-guided percutaneous lung biopsy[J].journal interventional radiology,2020,29(06):468.
[7]彭金钊,李晓光.肺癌热消融术后支气管胸膜瘘的研究现状与进展[J].介入放射学杂志,2020,29(12):1276.
 PENG Jinzhao,LI Xiaoguang..Bronchopleural fistula after thermal ablation of lung cancer: its research status and progress[J].journal interventional radiology,2020,29(06):1276.
[8]李向阳,穆 峰,陈继冰,等.CT引导下经皮冷冻消融治疗肺磨玻璃结节的研究[J].介入放射学杂志,2021,30(10):1072.
 LI Xiangyang,MU Feng,CHEN Jibing,et al.CT-guided percutaneous cryoablation for the treatment of pulmonary ground- glass nodules[J].journal interventional radiology,2021,30(06):1072.
[9]杨 波,刘念龙,沈晓康,等.MRI引导肺癌射频消融治疗的临床应用[J].介入放射学杂志,2021,30(11):1133.
 YANG Bo,LIU Nian-long,SHEN Xiao-kang,et al.Clinical application of MRI-guided radiofrequency ablation for lung cancer[J].journal interventional radiology,2021,30(06):1133.
[10]洪子强,白向豆,崔百强,等.经皮射频消融与微波消融治疗肺癌有效性及安全性的Meta分析 [J].介入放射学杂志,2023,32(04):341.
 HONG Ziqiang,BAI Xiangdou,CUI Baiqiang,et al.The effectiveness and safety of percutaneous radiofrequency ablation versus microwave ablation in the treatment of lung cancer: a meta analysis[J].journal interventional radiology,2023,32(06):341.

更新日期/Last Update: 2020-06-16